Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 13, 2022
Involvement of Patients and Medical Professionals in the Assessment of Relative Effectiveness: A Need for Closer Cooperation
Paulus Lips, Lonneke Timmers, Roland Bal, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 8, 2024
The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands
Ghyli Kirshner, Peter Makai, Chiara Brouns, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
September 15, 2021
[The assessment of the price of a medicine: not only on the basis of the value for the patient]
Carla E M Hollak, Sibren van den Berg, Lonneke Timmers, et al.
Patient Preference and Adherence
|
July 23, 2013
Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions
Jacqueline G Hugtenburg, Lonneke Timmers, Petra Jm Elders, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 28, 2025
Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products
Sibren van den Berg, Carolina E Hollak, Lonneke Timmers, et al.
Pharmacoeconomics
|
May 22, 2026
Using Proportional and Absolute Shortfall in Reimbursement Decision-Making in the Netherlands: Implications for Oncology Drugs for Older Patients
Vivian Reckers-Droog, Steef Redeker, Jan Busschbach, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 15, 2022
Author Reply
Sibren van den Berg, Saco J de Visser, Lonneke Timmers, et al.
Journal of Market Access & Health Policy
|
August 27, 2025
Preparing for the EU HTA Regulation: Insights from the Dutch Perspective
Anne Willemsen, Maureen Rutten-van Mölken, Riam Al Dulaimi, et al.
International Journal of Technology Assessment in Health Care
|
November 17, 2025
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands
Jan-Willem Versteeg, Noraly Stam, Aukje K Mantel-Teeuwisse, et al.
Pharmacoepidemiology and Drug Safety
|
September 30, 2011
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008
Lonneke Timmers, Jan Jacob Beckeringh, Myrthe P P van Herk-Sukel, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 13, 2022
Involvement of Patients and Medical Professionals in the Assessment of Relative Effectiveness: A Need for Closer Cooperation
Paulus Lips, Lonneke Timmers, Roland Bal, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 8, 2024
The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands
Ghyli Kirshner, Peter Makai, Chiara Brouns, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
September 15, 2021
[The assessment of the price of a medicine: not only on the basis of the value for the patient]
Carla E M Hollak, Sibren van den Berg, Lonneke Timmers, et al.
Patient Preference and Adherence
|
July 23, 2013
Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions
Jacqueline G Hugtenburg, Lonneke Timmers, Petra Jm Elders, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 28, 2025
Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products
Sibren van den Berg, Carolina E Hollak, Lonneke Timmers, et al.
Pharmacoeconomics
|
May 22, 2026
Using Proportional and Absolute Shortfall in Reimbursement Decision-Making in the Netherlands: Implications for Oncology Drugs for Older Patients
Vivian Reckers-Droog, Steef Redeker, Jan Busschbach, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 15, 2022
Author Reply
Sibren van den Berg, Saco J de Visser, Lonneke Timmers, et al.
Journal of Market Access & Health Policy
|
August 27, 2025
Preparing for the EU HTA Regulation: Insights from the Dutch Perspective
Anne Willemsen, Maureen Rutten-van Mölken, Riam Al Dulaimi, et al.
International Journal of Technology Assessment in Health Care
|
November 17, 2025
Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands
Jan-Willem Versteeg, Noraly Stam, Aukje K Mantel-Teeuwisse, et al.
Pharmacoepidemiology and Drug Safety
|
September 30, 2011
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008
Lonneke Timmers, Jan Jacob Beckeringh, Myrthe P P van Herk-Sukel, et al.
Page
of 4